

Fig. 1




Fig. 2




Fig. 3



Fig. 4





Fig. 5

Fig. 6




Fig. 7




Fig. 7a

Fig. 7b

Fig. 8





Fig. 9*Fig. 9a**Fig. 9b*


Fig. 10


Fig. 11

Fig. 12A.




Fig. 12B.

	WB	WB
IVIG	Comp	Fas-Comp
98J30AB12	Negative	Positive
99A18AB11	Negative	Positive
98K13AB12	Negative	Positive
2620M081A	Negative	Positive
99A13AB11	Negative	Positive
2453397F	Negative	Positive
2456898I	Negative	Positive
2470797G	Negative	Positive
2454198F	Negative	Positive
2470597G	Negative	Positive
Sandoglobulin	Negative	Positive
Anti-Fas Apo1	Negative	Positive
Vehicle	Negative	Negative

Fig. 13A.





Fig. 13B.

FasL ELISA Inhibition		
IVIG	% Max at 30 mg/ml	Categories
98J30AB12	45	2
99A18AB11	49	2
98K13AB12	49	2
2620M081A	60	Best
99A13AB11	44	2
2453397F	26	Worst
2456898I	36	3
2470797G	39	3
2454198F	45	2
2470597G	48	2
Sandoglobulin	35	3
Vehicle	100% binding	
1 hr Preincubation		

Fig. 13C.



Applicant(s): Lars E. French et al.

METHODS AND COMPOSITIONS FOR TREATING DISEASES
ASSOCIATED WITH INCREASED FAS-LIGAND TITERS

Fig 14A.




Fig 14B.

IVIG	FasL Killing Inhibition		Categories
	Start mg/ml	Peak mg/ml	
98J30AB12	0.5	4	2
99A18AB11	1	8	3
98K13AB12	1	8	3
2620M081A	2	8	4
99A13AB11	1	15	4
2453397F	1	4	2
2456898I	1	4	2
2470797G	1	4	2
2454198F	0.25	8	Best
2470597G	0.25	8	Best
Sandoglobulin	15	30	Worst
Vehicle	Negative	Negative	
	No Preincubation	No Preincubation	

Fig. 14C.

